In 2022, around 10 percent of the Black U.S. population reported currently having asthma, while the percentage for the Hispanic population amounted to 6.7 percent. This statistic represents the percentage of the U.S. population with current asthma from 2001 to 2022, sorted by race and ethnicity.

As of 2022, the prevalence of current asthma among U.S. children was around six percent. Females had higher rates of asthma than males, with almost 10 percent of females currently suffering from asthma. This statistic represents the current asthma prevalence in the United States in 2022, sorted by gender, age, and race/ethnicity.

In 2022, the prevalence of current asthma among U.S. non-Hispanic Black females of all ages was 12.1 percent. In comparison, around 7.6 percent of Hispanic females had current asthma at that time.

In 2022, the prevalence of current asthma among U.S. non-Hispanic Black children and adolescents was 11.2 percent. In comparison, around 5.5 percent of Hispanic children and adolescents under the age of 18 had current asthma at that time.

In 2022, the prevalence of current asthma among U.S. non-Hispanic Black adults was 10.1 percent. In comparison, around 7.2 percent of Hispanic adults had current asthma at that time.

BackgroundChronic Obstructive Pulmonary Disease (COPD), mainly caused by cigarette smoking, is one of the leading causes of death in the United States (US) and frequent asthma attacks are often exacerbated by cigarette use. Electronic cigarettes (e-cigarettes) are often used to quit cigarette smoking. Prevalence of COPD, asthma, cigarette use, and e-cigarette use differs between racial/ethnic groups. The overall objective was to assess the associations between e-cigarette use and COPD and asthma and how race/ethnicity and cigarette smoking modifies these associations.MethodsData were retrieved from the 2016–2018 and 2020–2021 Behavioral Risk Factor Surveillance System datasets, a national annual health survey representing the US general adult population. Frequency and weighted percentages or means and standard deviations were obtained. Rao-Scott Chi-square test, two-sample t tests, and logistic regression were used to evaluate binary associations between current e-cigarette use and lifetime diagnosis of COPD and asthma. Multivariable analyses using logistic regression were conducted to assess associations between variables. Interaction effects between e-cigarette use and race/ethnicity were assessed and stratified analyses were performed as indicated. All multivariate analyses were stratified by cigarette smoking status.ResultsPrevalence of e-cigarette use was 5.1%, COPD was 6.7%, and asthma was 9.2%. Individuals who currently smoked cigarettes among all racial/ethnic groups, excluding non-Hispanic (NH) American Indian/Alaska Native individuals, were more likely to report current asthma if using e-cigarettes compared to non-use (p 

This dataset contains counts and rates (per 10,000 residents) of asthma hospitalizations among Californians statewide and by county. The data are stratified by age group (all ages, 0-17, 18+, 0-4, 5-17, 18-64, 65+) and race/ethnicity (white, black, Hispanic, Asian/Pacific Islander, American Indian/Alaskan Native). The data are derived from the Department of Health Care Access and Information Patient Discharge Data. These data include hospitalizations from all licensed hospitals in California. These data are based only on primary discharge diagnosis codes. On October 1, 2015, diagnostic coding for asthma transitioned from ICD-9-CM (493) to ICD-10-CM (J45). Because of this change, CDPH and CDC do not recommend comparing data from 2015 (or earlier) to 2016 (or later). NOTE: Rates are calculated from the total number of asthma hospitalizations (not the unique number of individuals).

Objective: To provide updated prevalence estimates of asthma and asthma medication use for women of childbearing age in the United States. Methods: Using data from 11,383 women aged 18–44, including a subset of 1,245 pregnant women, enrolled in the National Health and Nutrition Examination Survey (2001–2016), we assessed the age-adjusted prevalence of self-reported diagnosed asthma. For women aged 18–44, we stratified by year, demographics, and other characteristics. Furthermore, we assessed asthma medication use among women aged 18–44 with asthma. Results: After age-adjustment, 9.9% (95% confidence interval (CI) 9.2%, 10.7%) of women aged 18–44 and 10.9% (95% CI 7.2%, 14.6%) of pregnant women reported having asthma. Asthma prevalence was highest in 2015–2016 (12.0% 95% CI 9.8%, 14.3%) and lowest in 2003–2004 (8.6% 95% CI 6.4%, 10.8%). Women aged 18–44 with Medicaid or State Children’s Health Insurance Program insurance coverage (16.8% 95% CI 14.5%, 19.2%), obesity (14.4% 95% CI 12.9%, 15.8%), diabetes (18.7% 95% CI 12.1%, 25.2%), hypertension (16.6% 95% CI 14.2%, 19.0%), and current smokers (12.8% 95% CI 11.4%, 14.2%) had the highest asthma prevalence. Of women with asthma, 38.3% (95% CI 34.5%, 42.1%) reported using asthma medications in the past 30 days. Conclusions: Among women of childbearing ages, asthma burden varies across demographic and clinical characteristics and has increased in recent years.

In the period from 2019 to 2021, around 43 percent of white children in the United States with asthma had one or more asthma attacks in the past 12 months. This statistic shows the percentage of children aged 0-17 years in the U.S. with asthma who had one or more asthma attacks in the past year from 2019 to 2021, by racial and ethnic group.

In the period from 2019-2021, around 42 percent of white adults in the United States with asthma had one or more asthma attacks in the past 12 months. This statistic shows the percentage of adults in the U.S. with asthma who had one or more asthma attacks in the past year as of 2019-2021, by racial and ethnic group.

There are 750,000 emergency department (ED) visits by children for asthma exacerbations in the United States annually. Despite changing evidence and epidemiology, there have not been recent assessments of acute asthma prevalence, management, and outcomes from pediatric EDs. This 40-center retrospective evaluation utilizes the Pediatric Hospital Information System to characterize pediatric ED asthma presentations from 2015-2020. Children 2-18 years with asthma ICD-9/10 code and receipt of albuterol were included. Demographics, Child Opportunity Index (COI), ED management, return visits, and adjusted costs were evaluated. Data were summarized using standard descriptive statistics and trends assessed using Mann-Kendall trend test. There were 414,264 encounters made by 256,209 unique patients; 21% had >1 visit in 12 months. Median age was 6 years, 61.6% male, 44.5% Black, and 68.5% publicly insured; 58.3% of visits were by patients with very low/low COI. Systemic corticosteroids were administered in 86.3% of visits; 52.7% used dexamethasone. Chest radiographs were obtained in 23% of encounters. Most (74.9%) encounters resulted in ED discharge with a downward trend of visits for exacerbations per 1,000 ED visits of -9.77, 95% CI [-9.99,-9.54], increase in disposition to intensive care unit of 2.01 [1.87,2.41] and decrease in home/other of -3.77 [-4.34,-3.20]. There was no significant trend in return visits. Total adjusted costs were ∼$900 million. ED visits for asthma remain frequent and disproportionately affect children with lower social determinants of health. Dexamethasone has not been widely adopted as corticosteroid of choice and use of ancillary testing continues, highlighting opportunities for improvement in asthma care.

This dataset contains counts and rates (per 10,000 residents) of asthma emergency department (ED) visits among Californians. The table “Asthma Emergency Department Visit Rates by County” contains statewide and county-level data stratified by age group (all ages, 0-17, 18+, 0-4, 5-17, 18-64, 65+) and race/ethnicity (white, black, Hispanic, Asian/Pacific Islander, American Indian/Alaskan Native). The table “Asthma Emergency Department Visit Rates by ZIP Code” contains zip-code level data stratified by age group (all ages, 0-17, 18+). The data are derived from the Department of Health Care Access and Information emergency department database. These data include emergency department visits from all licensed hospitals in California. These data are based only on primary discharge diagnosis codes. On October 1, 2015, diagnostic coding for asthma transitioned from ICD9-CM (493) to ICD10-CM (J45). Because of this change, CDPH and CDC do not recommend comparing data from 2015 (or earlier) to 2016 (or later). NOTE: Rates are calculated from the total number of asthma emergency department visits (not the unique number of individuals).

This dataset, curated by PIONEER, encompasses a detailed collection of 181,207 asthma admissions from 1st June 2016 to 31st May 2022, offering a comprehensive analysis tool for researchers examining the effects of air quality on respiratory health. It includes extensive patient demographics, serial physiological measurements, assessments, diagnostic codes (ICD-10 and SNOMED-CT), initial presentations, symptoms, and outcomes. Additionally, it integrates DEFRA air pollution data, geographically linked t individual health data, allowing for a nuanced exploration of environmental impacts on asthma incidence and severity. The dataset includes 4 years of data prior to and currently 1 year post introduction of the clean air zone.

The dataset invites longitudinal studies to evaluate the Clean Air Zones' effectiveness. Timelines post-introduction of the clean air zone can be expanded to include data up to 2024. Its granular detail provides invaluable insights into emergency medicine, public health policy, and environmental science, supporting targeted interventions and policy formulations aimed at reducing asthma exacerbations and improving air quality standards.

Geography: The West Midlands (WM) has a population of 6 million & includes a diverse ethnic & socio-economic mix. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact pioneer@uhb.nhs.uk or visit www.pioneerdatahub.co.uk for more details.

Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in OMOP and other common data models and can build synthetic data to meet bespoke requirements.

Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment (TRE) build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.

Montelukast Sodium Preparations Market Outlook

The global Montelukast Sodium Preparations market size was valued at approximately $4.2 billion in 2023 and is projected to reach about $6.8 billion by 2032, growing at a CAGR of 5.5% from 2024 to 2032. This substantial growth is driven by a combination of factors including the rising prevalence of asthma and allergic rhinitis, increased awareness of the benefits of Montelukast Sodium, and advances in medical research and pharmaceuticals.

The rising incidence of asthma and allergic rhinitis worldwide is a significant growth factor for the Montelukast Sodium Preparations market. According to the World Health Organization, asthma affects around 235 million people globally, and this number is growing due to urbanization and increased pollution levels. Montelukast Sodium, being a leukotriene receptor antagonist, offers a more targeted approach to managing asthma and related respiratory conditions, thus driving its demand. Additionally, allergic rhinitis, which often coexists with asthma, is becoming more prevalent, further boosting the need for effective treatment options like Montelukast Sodium preparations.

Innovations in pharmaceutical formulations and the development of more patient-friendly dosage forms also contribute significantly to market growth. The introduction of chewable tablets and oral granules has made Montelukast Sodium more accessible, particularly for pediatric and geriatric patients who may have difficulty swallowing traditional tablets. This diversification in product offerings not only enhances patient compliance but also expands the market reach to different patient demographics. Moreover, ongoing research and clinical trials aim to explore new therapeutic applications for Montelukast Sodium, potentially unlocking additional market opportunities.

Healthcare infrastructure improvements and increased healthcare spending in emerging economies are other key factors propelling the Montelukast Sodium Preparations market. In countries like India, China, and Brazil, rising disposable incomes and a growing middle class are leading to greater access to healthcare services and medications. Government initiatives to improve public health and expand healthcare coverage are also supportive. As a result, pharmaceutical companies are increasingly focusing on these high-growth markets, investing in local manufacturing facilities, and strategic partnerships to capitalize on the growing demand for Montelukast Sodium preparations.

Regionally, North America dominates the Montelukast Sodium Preparations market, driven by high healthcare expenditure, advanced healthcare infrastructure, and a large patient pool. However, the Asia Pacific region is expected to exhibit the highest growth rate during the forecast period. This growth is attributed to the increasing prevalence of asthma and allergic conditions, improving healthcare systems, and rising awareness about the benefits of Montelukast Sodium. Europe also holds a significant market share, supported by well-established healthcare systems and high per capita healthcare spending.

Product Type Analysis

The Montelukast Sodium Preparations market is segmented by product type into Tablets, Chewable Tablets, and Oral Granules. Tablets continue to be the most widely used form of Montelukast Sodium, primarily due to their established efficacy, ease of production, and widespread acceptance among adult patients. Tablets are often the preferred choice in clinical settings for treating chronic conditions like asthma and allergic rhinitis. The ease of dosage and the ability to incorporate sustained-release formulations further enhance their utility in managing long-term conditions.

Chewable tablets are gaining popularity, particularly among pediatric and geriatric patients who may have difficulty swallowing conventional tablets. The palatable flavor and ease of use make chewable tablets a preferred option for children, enhancing medication adherence and improving treatment outcomes. Pharmaceutical companies are increasingly focusing on developing chewable formulations that are both effective and palatable, thereby catering to a broader patient demographic. This sub-segment is expected to witness substantial growth during the forecast period, driven by increasing formulation innovations and rising demand for pediatric-friendly medications.

Oral granules represent another significant segment within the Montelukast Sodium Preparations market. These granules offer a convenient and flexible mode of administration, especially for young children and

Autoimmunity prevalence, as measured by antinuclear antibodies (ANA), is increasing in U.S. adolescents. Improved hygiene and cleaner environments in childhood may reduce exposure to infections and other immune challenges, resulting in improper immune responses to later-life exposures. We examined associations of hygiene hypothesis indicators, including asthma, allergies, and antibodies to infectious agents, with ANA prevalence, measured by HEp-2 immunofluorescence, in adolescents (aged 12-19 years) over a 25-year time span in the National Health and Nutrition Examination Survey (NHANES) (N=2,709), adjusting for age, sex, race/ethnicity, body mass index, education and survey cycle, overall and within individual time periods, using logistic regression. Prevalence of ANA in adolescents increased from 5.0% in 1988-1991 to 12.8% in 2011-2012. ANA were positively associated with diagnosis of asthma in early childhood (OR: 2.07, CI: 1.09–3.99) and the effect estimate for current hay fever was elevated but not statistically significant (OR: 1.55, CI: 0.85–2.84). Fewer than 2% of those with ANA in 1988-1991 had been diagnosed with asthma, compared with 18% in 1999-2000, and 27% in 2003-2004 and 2011-2012. ANA trended negatively with Helicobacter pylori antibodies (OR: 0.49, CI: 0.24–0.99). ANA may be useful as an additional indicator of inadequate immune education in adolescence, a critical period of growth and development.